Quarterly report pursuant to Section 13 or 15(d)

Earnings (Loss) Per Common Share

v3.25.0.1
Earnings (Loss) Per Common Share
6 Months Ended
Dec. 31, 2024
Earnings (Loss) Per Common Share  
Earnings (Loss) Per Common Share

16.   Earnings (Loss) Per Common Share

Basic earnings (loss) per common share is computed by dividing the net income (loss) allocated to common stockholders by the weighted-average number of shares of Common Stock outstanding during the period. For purposes of calculating diluted earnings (loss) per common share, the denominator includes both the weighted-average number of shares of Common Stock outstanding during the period and the number of common stock equivalents if the inclusion of such common stock equivalents is dilutive. Dilutive common stock equivalents potentially include stock options and warrants using the treasury stock method. The following table summarizes the components of the earnings (loss) per common share calculation (in thousands, except per share amounts):

Three Months Ended

Six Months Ended

December 31, 

December 31, 

    

2024

    

2023

2024

    

2023

Basic and diluted numerator:

Net loss from continuing operations

$

(4,364)

$

(4,488)

$

(8,353)

$

(9,562)

Net loss from discontinued operations

$

$

(3,723)

$

$

(4,395)

Net loss - total

$

(4,364)

$

(8,211)

$

(8,353)

$

(13,957)

Basic and diluted denominator:

Weighted-average common shares outstanding

 

9,132

 

1,856

 

8,880

 

1,525

 

 

 

 

Per share amount - continuing operations

$

(0.48)

$

(2.42)

$

(0.94)

$

(6.27)

Per share amount - discontinued operations

$

$

(2.00)

$

$

(2.88)

Per share amount - total

$

(0.48)

$

(4.42)

$

(0.94)

$

(9.15)

In Fiscal 2025 and Fiscal 2024, the Company incurred net losses which cannot be diluted; therefore, basic and diluted loss per common share is the same. As of December 31, 2024 and 2023, shares issuable which could potentially dilute future earnings were as follows:

December 31, 

    

2024

    

2023

(in thousands)

Stock options

 

1,058

 

36

Restricted stock units

    

12

    

3

Warrants

11,521

5,339

AstralBio Exclusive License Agreement

246

Shares excluded from the calculation of diluted loss per share

 

12,837

 

5,378